ZyVersa Therapeutics Inc. (NASDAQ: ZVSA) Stock Information | RedChip
Image

ASK REDCHAT® ANYTHING ABOUT ZYVERSA THERAPEUTICS INC.

ZyVersa Therapeutics Inc. (NASDAQ: ZVSA)
Listen to this Section


$1.30
+0.0120 ( -0.39% ) 42.3K

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Market Data


Open $1.30
Previous Close $1.28
Volume 42.3K
Market Cap $1.39M
Day Range $1.26 - $1.31
52 Week Range $0.98 - $25.00
Shares Outstanding 1.07M
Change % -0.39%
Net Change ▲ 0.0120
Insider Ownership N/A
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology: Pharmaceutical Preparations
IPO Year 2022
Country United States
Under Writer A.G.P., Brookline Capital Markets, more

Insider Ownership Transactions

Total Amount Purchased: -3,442.00

Date Type Amount Purchased Purchaser
2024-07-18 Sale -132.00 Freitag Gregory Gene
2024-07-18 Sale -572.00 Cashmere Karen A.
2024-07-18 Sale -132.00 Park Min-Chul
2024-07-18 Sale -132.00 Finizio Robert G
2024-07-18 Sale -132.00 SAPIRSTEIN JAMES
2024-07-18 Sale -1627.00 Glover Stephen C.
2024-07-18 Sale -715.00 Wolfe Peter

Institutional Ownership

Total Market Value $ 0.00

Symbol Issuer Name Market Value ↓ Share Quantity
No records found.

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 2 Jul 18, 2024
4 Insider transactions 2 Jul 18, 2024
4 Insider transactions 1 Jul 18, 2024
4 Insider transactions 2 Jul 18, 2024
effect Other 1 Jul 16, 2024
pos Registration statements 95 Jul 12, 2024
10-k/a Quarterly Reports 16 May 15, 2024
10-q Quarterly Reports 55 May 15, 2024
8-k 8K-related 14 Apr 25, 2024
8-k 8K-related 13 Apr 17, 2024

Latest News


× Before browsing our site, please accept our cookies policy